Live Analyst Rating Changes 53484 upgrades, downgrades & price-target moves · freshest Wall Street data, updated daily View live feed →
Analyst Tracker/Ashwani Verma
UBS

Ashwani Verma

UBS
Wall Street Analyst
★★★★☆
#492
on 13Foresight · ranked by our own returns
60%
Success Rate
+7.3%
Average Return
49 of 81 calls profitable · +2.8% vs benchmark
S&P 500 (SPY)
📈 Across the calls we could measure, roughly 60% of Ashwani Verma's ratings turned a profit when each position was held for 2 year — averaging +7.3% per rating. These figures are computed by 13Foresight from historical prices, not supplied by the analyst.

Rating Distribution

69 Buy 25 Hold 0 Sell
Ashwani's Stock Coverage 28 ratings · 2026-11-04
Company Date Position Consensus ⓘ Price Target ⓘ 2-Yr Return vs S&P 500 ⓘ
INCY
Incyte
 Oct 30, 2026 HOLD Buy
-5.9% avg upside
49 analysts
$127.00
5.50% Upside
 +0.0% ·
INSM
Insmed
 Oct 30, 2026 BUY Strong Buy
+51.3% avg upside
37 analysts
$172.00
52.87% Upside
 -7.2% ·
JAZZ
Jazz Pharmaceuticals
 Oct 28, 2026 BUY Strong Buy
+16.2% avg upside
36 analysts
$337.00
55.94% Upside
 +12.9% ·
LEGN
Legend Biotech
 Oct 27, 2026 HOLD Strong Buy
+182.2% avg upside
27 analysts
$24.00
11.05% Upside
 +5.6% ·
ALVO
Alvotech
 Oct 20, 2026 BUY Strong Buy
+87.4% avg upside
7 analysts
$8.00
72.03% Upside
 -9.2% ·
CYTK
Cytokinetics
 Oct 15, 2026 BUY Strong Buy
+43.4% avg upside
36 analysts
$104.00
65.07% Upside
 -1.4% ·
MDGL
Madrigal Pharmaceuticals
 Oct 15, 2026 BUY Strong Buy
+20.2% avg upside
34 analysts
$735.00
70.76% Upside
 -12.9% ·
ACAD
ACADIA Pharmaceuticals
 Oct 14, 2026 HOLD Strong Buy
+71.5% avg upside
43 analysts
$23.00
11.61% Upside
 +7.0% ·
UTHR
United Therapeutics
 Oct 13, 2026 BUY Buy
-22.7% avg upside
27 analysts
$725.00
21.05% Upside
 +10.7% ·
VTRS
Viatris
 Oct 05, 2026 BUY Buy
+25.5% avg upside
22 analysts
$26.00
36.59% Upside
 +6.0% ·
NBIX
Neurocrine
 Sep 28, 2026 BUY Strong Buy
+27.3% avg upside
37 analysts
$214.00
46.46% Upside
 +4.0% ·
RPRX
Royalty Pharma
 Sep 08, 2026 BUY Strong Buy
-12.2% avg upside
15 analysts
$66.00
1.80% Downside
 +11.5% ·
ASMB
Assembly Biosciences
 Sep 01, 2026 BUY Strong Buy
+82.7% avg upside
11 analysts
$52.00
158.42% Upside
 -42.7% ·
MPLT
MapLight Therapeutics, Inc.
 Aug 11, 2026 HOLD Strong Buy
+288.1% avg upside
14 analysts
$13.00
71.45% Upside
 -43.2% ·
AMRX
Amneal Pharmaceuticals
 Aug 03, 2026 BUY Strong Buy
-10.1% avg upside
19 analysts
$25.00
16.24% Upside
 +5.8% ·
EXEL
Exelixis
 Jul 02, 2026 HOLD Buy
-34.0% avg upside
34 analysts
$52.00
25.14% Downside
 +29.5% ·
BHVN
Biohaven Ltd.
 May 28, 2026 HOLD Buy
+51.3% avg upside
25 analysts
$11.00
28.59% Downside
 +49.5% ·
CORT
Corcept Therapeutics
 May 13, 2026 BUY Buy
-17.9% avg upside
16 analysts
$72.00
11.30% Downside
 +36.5% ·
ALKS
Alkermes
 May 06, 2026 BUY Strong Buy
-3.4% avg upside
34 analysts
$48.00
5.91% Upside
 +27.1% ·
AXSM
Axsome Therapeutics
 Apr 10, 2026 BUY Strong Buy
+63.9% avg upside
30 analysts
$259.00
79.25% Upside
 -22.4% ·
ABBV
AbbVie
 Nov 07, 2025 HOLD Strong Buy
-14.5% avg upside
47 analysts
$220.00
25.36% Downside
 +38.6% ·
LLY
Eli Lilly & Co
 Nov 07, 2025 BUY Strong Buy
-16.7% avg upside
50 analysts
$1080.00
23.75% Downside
 +53.6% ·
HRMY
Harmony Biosciences Holdings
 Oct 14, 2025 BUY Strong Buy
+27.3% avg upside
14 analysts
$43.00
10.92% Upside
 +37.9% ·
IMVT
Immunovant
 Jul 29, 2025 HOLD Strong Buy
+38.4% avg upside
25 analysts
$18.00
38.20% Downside
 +76.7% ·
CHRS
Coherus Biosciences
 Jul 21, 2025 HOLD Buy
+1336.6% avg upside
19 analysts
$1.10
32.59% Upside
 -15.5% ·
BIIB
Biogen
 Jul 14, 2025 HOLD Strong Buy
+6.6% avg upside
53 analysts
$130.00
48.80% Downside
 +90.5% ·
RCKT
Rocket Pharmaceuticals
 Jun 17, 2025 BUY Buy
+546.4% avg upside
30 analysts
$5.00
104.97% Upside
 -9.2% ·
RANI
Rani Therapeutics Holdings
 Oct 11, 2022 BUY Strong Buy
+1444.2% avg upside
10 analysts
$15.00
2442.29% Upside
 -74.8% ·
🔒 23 more ratings — with price targets, crowd consensus and our measured returns.
Sign in free to unlock See Pro plans
Free account unlocks every analyst's full coverage table.
Ashwani Verma — Frequently Asked Questions
How accurate are Ashwani Verma's stock ratings?
Based on the calls 13Foresight could measure, about 62% of Ashwani's ratings were profitable over a one-year hold, with an average return of +8.6% per rating, or +4.7% versus the S&P 500. We score every analyst the same way, from historical prices. Each return is measured in the stock's own trading currency, so for non-US listings the S&P 500 comparison leaves out currency moves.
How is Ashwani ranked on 13Foresight?
Ashwani Verma is currently ranked #492 with a 4-star rating. Our rank blends hit rate, average return versus the market, and how many calls we have to judge — so a long, consistent record outweighs a few lucky picks. It is our own calculation, updated daily.
Which stocks does Ashwani cover?
Ashwani most recently has ratings on INCY, INSM, JAZZ, LEGN, ALVO, CYTK, MDGL, ACAD, UTHR, VTRS, NBIX, RPRX and 16 more. See the full coverage table above for positions, price targets and our measured returns.
Where can I see other analyst ratings?
Browse the full analyst leaderboard to compare Wall Street analysts ranked by their measured performance, success rate and average return.

Disclaimer: 13Foresight compiles analyst ratings and price targets from publicly available sources. Performance metrics, rankings and star ratings shown here are calculated independently by 13Foresight from historical market prices and may differ from figures published elsewhere. This information may be incomplete, delayed or inaccurate, is provided for research and informational purposes only, and is not investment advice. The underlying ratings and opinions are those of the respective analysts and their firms; 13Foresight accepts no liability for any decisions made based on this data.